Illumina (ILMN) raised its 2026 revenue and EPS guidance following a 9.5% year-over-year revenue increase in Q2, driven by strong oncology clinical growth and expanded multiomics offerings. However, the company faces margin pressure from tariffs, freight costs, and memory inflation, with adjusted gross margin declining 120 basis points year-over-year despite manageable leverage and sufficient liquidity.

Teleflex (TFX), a Zacks Rank #2 (Buy) stock, benefits from strong growth in its Vascular business driven by central access demand, hemostatic products, and FDA approval of EZPLAZ. The Interventional platform is expanding through the BIOTRONIK acquisition with promising clinical development of Freesolve. However, foreign exchange sensitivity remains a key concern. The company has improved balance sheet flexibility with net leverage declining to 1.9X following strategic divestitures.

In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank #1 (Strong Buy) with a Value grade of B, featuring a lower forward P/E ratio of 16.86 and PEG ratio of 1.35. ITGR carries a Zacks Rank #3 (Hold) with a Value grade of C, posting a higher forward P/E of 20.55 and PEG ratio of 2.96. Based on valuation metrics and earnings outlook, GMED is positioned as the more attractive choice for value investors.

Veeva Systems (VEEV) reported Q2 fiscal 2027 adjusted EPS of $2.35, up 18.1% YoY and beating consensus by 5.9%, with revenues rising 17.6% to $928 million. The company raised its fiscal 2027 revenue guidance to $3.682-$3.687 billion and EPS to $9.21. Vault CRM momentum continued with over 180 customers live including five top 20 biopharmas, while the company advanced its AI strategy with Veeva Falcon.

Globus Medical, Inc. announced the acquisition of Higgs Boson Health, a Durham, NC-based digital healthcare company incubated from Duke University. The acquisition aims to enhance Globus Medical's ecosystem by integrating AI-driven digital solutions and surgical intelligence capabilities to improve patient outcomes in musculoskeletal surgeries, with a goal of achieving 95% good outcomes at 10 years.

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.

The global spinal implants market was valued at USD 11.5 billion in 2024 and is projected to reach USD 15.8 billion by 2030, growing at a CAGR of 5.5%. Growth is driven by an aging global population, rising traumatic injuries, and advancements in minimally invasive spine surgery. Spinal fusion devices dominate the market, while Asia Pacific is expected to show the highest growth rate during the forecast period.

The global Pedicle Screw Systems Market is projected to grow from $2.38 billion in 2025 to $3.71 billion by 2033, with a 5.76% CAGR, driven by rising spinal disorder prevalence and technological advancements in spine surgery.

Multiple large-cap companies reported strong Q3 earnings and raised fiscal year guidance, leading to significant stock price gains across various sectors including technology, travel, and healthcare.

Globus Medical announced leadership transitions, with Keith Pfeil becoming President and CEO, replacing Dan Scavilla. Kyle Kline was appointed as the new CFO. The company reported preliminary Q2 2025 sales of $745.3 million, an 18.4% increase from the previous year.

The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation devices.

Globus Medical, a leading musculoskeletal technology company, has completed the acquisition of Nevro Corp., a global medical device company that specializes in the treatment of chronic pain. The acquisition expands Globus Medical's presence in the musculoskeletal market and provides access to Nevro's differentiated high-frequency technology.